CClinicalTrials.gg
Not yet recruitingNCT07540156Updated Apr 20, 2026

Evaluation of the Safety, Feasibility, and Early Clinical Outcomes of Patient-Specific Bone Defect Implants Fabricated From Titanium Alloy (Ti-6Al-4V) Using 3D Printing Technology

An interventional study of Patient-specific 3D-printed Ti-6Al-4V bone implant in Bone Loss and Bone Defects, sponsored by VinUniversity. Not yet recruiting at 1 site in Vietnam. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by VinUniversity · Not applicable, Interventional, and Device feasibility

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the safety and feasibility of patient-specific bone defect implants fabricated from Ti-6Al-4V using 3D printing technology and to assess early clinical outcomes within the first 12 months following implantation of these customized devices. The main question it aims to answer is: "In patients with bone defects requiring surgical reconstruction, are patient-specific bone defect implants fabricated from titanium alloy (Ti-6Al-4V) using 3D printing technology - designed and produced at VinUni, safe and feasible for clinical use, and do they result in favorable early clinical outcomes within the first 12 months following implantation?"

Read the detailed description

Bone defects resulting from trauma, tumor resection, infection, or congenital abnormalities represent a significant clinical burden in orthopedic and reconstructive surgery worldwide. Large or complex bone defects often lead to prolonged disability, functional impairment, and reduced quality of life if not appropriately treated. According to the World Health Organization (WHO), each year there are approximately 20-50 million non-fatal road traffic injuries globally, many of which are associated with fractures and segmental bone loss requiring surgical intervention.1 In addition, age-related musculoskeletal disorders such as osteoporosis, which affects an estimated 200 million people worldwide, further increase the incidence of bone defects and fracture-related complications.2 Epidemiological studies have shown that bone loss following tumor resection, severe trauma, or chronic infection remains a major challenge due to limited regenerative capacity and high mechanical demands at defect sites. Traditional reconstruction methods, including autologous and allogeneic bone grafting, although widely applied, are associated with several limitations such as donor-site morbidity, limited graft availability, risk of infection transmission, prolonged treatment time, and difficulty in achieving optimal anatomical reconstruction.3,4 As a result, bone reconstruction using artificial implantable materials has emerged as a promising therapeutic strategy. Among available options, artificial bone implants based on metallic biomaterials, particularly titanium alloys, have gained increasing attention due to their ability to provide immediate mechanical stability and support biological integration.5-7 Titanium and titanium-based alloys have been extensively used in clinical bone implantation for several decades and are recognized as among the most reliable materials for skeletal reconstruction.5,7 These materials have demonstrated favorable mechanical strength, corrosion resistance, and excellent biocompatibility, allowing long-term implantation in the human body. Titanium implants have been successfully applied in a wide range of clinical settings, including cranial and craniofacial reconstruction, limb and long bone defect replacement, spinal fixation, and dental implantation.5 Regulatory authorities such as the U.S. Food and Drug Administration (FDA) have approved the use of titanium alloys, including Ti-6Al-4V, for implantable medical devices based on accumulated evidence of safety and effectiveness.6 Furthermore, international standards such as ISO 5832 and ISO 10993, and also Vietnamese national standard clearly define requirements for chemical composition, mechanical properties, and biocompatibility testing of titanium alloys used in medical implants.8-10 Numerous international and domestic studies have consistently reported low toxicity, minimal inflammatory response, and good osseointegration associated with titanium-based implants, thereby confirming their clinical safety and suitability for bone defect reconstruction.5-7 In recent years, additive manufacturing, commonly referred to as three-dimensional (3D) printing, has emerged as a major technological advancement in the fabrication of titanium alloy implants. Conventional manufacturing methods, such as casting, forging, or machining, often face limitations in producing complex geometries and patient-specific designs, particularly for irregular or large bone defects.6 In contrast, 3D printing technologies, especially laser-based techniques such as selective laser melting or laser powder bed fusion, enable the precise fabrication of Ti-6Al-4V implants based on individual patient anatomy.11 Using preoperative imaging data from computed tomography or magnetic resonance imaging, personalized implants can be digitally designed to closely match defect morphology. 12-15 This high level of design accuracy allows improved implant fit, optimized load transmission, and the incorporation of porous or lattice structures that enhance bone ingrowth and biological fixation.9,11 Consequently, 3D-printed titanium implants offer significant advantages in addressing complex bone defects where conventional implants may be inadequate.

Globally, a growing number of studies have investigated the clinical application of 3D-printed titanium implants in bone defect reconstruction and have reported encouraging early outcomes. International case series and clinical reports have described successful use of patient-specific 3D-printed Ti-6Al-4V implants in pelvic reconstruction following tumor resection, craniofacial and cranial defect repair, limb-salvage surgery, and complex defects of the foot and ankle.16-19 These studies have demonstrated acceptable safety profiles, satisfactory implant stability, favorable bone integration, and improvement in functional outcomes during early follow-up periods. Reviews published in international orthopedic and biomaterials journals have emphasized the advantages of personalized implant design and porous surface architecture in promoting osseointegration and functional recovery.17 In Vietnam, research and clinical implementation of 3D printing technology in bone implantation are rapidly developing, with increasing application in craniofacial surgery, orthopedic trauma, and oncology.20 However, most domestic reports remain limited to technical descriptions or isolated clinical cases, and prospective clinical studies with standardized evaluation of safety and early outcomes are still scarce.

Despite the growing international experience and emerging clinical applications in Vietnam, several critical gaps remain that justify the necessity of this study. according to the latest guidelines from the Ministry of Health, as high-risk medical devices (Class D), patient-specific 3D-printed titanium implants are required to undergo systematic clinical evaluation across Phase I, II, and III trials to rigorously demonstrate safety, feasibility, and clinical effectiveness prior to widespread clinical implementation.21 Although preliminary studies in Vietnam have investigated similar products, most available evidence remains limited to isolated cases or technical reports, with a lack of prospective, systematically designed clinical studies.22 Furthermore, differences in manufacturing systems, machine configurations, material handling, and process parameters across production facilities may substantially influence implant quality and clinical performance, thereby necessitating site-specific clinical evidence to confirm that implants fabricated at a given 3D printing laboratory are safe, feasible, and effective in patients.23,24 This study is therefore essential to address these regulatory and scientific requirements and to generate foundational clinical evidence supporting responsible clinical translation of 3D-printed titanium implants. In this context, the 3D Medical Technology Laboratory at VinUniversity serves as a site-specific manufacturing facility for patient-specific 3D-printed implants, operating in compliance with internationally recognized ISO standards for medical device production and being entrusted by the Ministry of Health, particularly the Department of Science, Technology and Training, to support clinical evaluation activities.25 This study is therefore essential to address these regulatory and scientific requirements and to generate foundational clinical evidence supporting the responsible clinical translation of 3D-printed titanium implants produced within this manufacturing system.

02

Conditions studied

  • Bone Loss
  • Bone Defects

Keywords

  • Bone defect reconstruction
  • Patient-specific implants
  • Three-dimensional (3D) printing
  • Titanium alloy Ti-6Al-4V
03

In context

Bone Diseases, Metabolic

470 studies on the registry are indexed under Bone Diseases, Metabolic; 71 are open to participants now.

This study's planned enrollment of 10 is below the median of 60 across 359 interventional studies indexed under Bone Diseases, Metabolic.

Browse Bone Diseases, Metabolic studies →

Lead sponsor

VinUniversity is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosed with a bone defect requiring surgical reconstruction, as determined by the treating orthopedic surgeon
  • Suitable candidate for implantation of a patient-specific device manufactured from Ti-6Al-4V
  • Able to undergo preoperative imaging (CT ± MRI) required for implant design
  • Willing and able to provide written informed consent
  • Willing to comply with scheduled follow-up visits and study assessments

Exclusion criteria

Exclusion Criteria:

  • Active systemic or local infection at the surgical site at the time of implantation
  • Known hypersensitivity or allergy to titanium or titanium alloys
  • Severe uncontrolled comorbidities that significantly increase surgical risk (e.g., uncontrolled diabetes, severe cardiovascular disease)
  • Pregnant or breastfeeding women
  • Participation in another interventional clinical study that may interfere with the outcomes of this study
  • Inability to complete follow-up assessments within the required timeframe
05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Patient-specific 3D-printed Ti-6Al-4V implant reconstruction

    Participants in this arm will undergo surgical reconstruction of bone defects using patient-specific implants fabricated from titanium alloy (Ti-6Al-4V) through three-dimensional (3D) printing technology. Implants are designed based on preoperative imaging data (CT ± MRI) and manufactured using laser powder bed fusion/selective laser melting. The study evaluates the safety, feasibility, and early clinical outcomes of these customized implants during a 12-month follow-up period.

    Device: Patient-specific 3D-printed Ti-6Al-4V bone implant

Interventions

  • DevicePatient-specific 3D-printed Ti-6Al-4V bone implant

    The investigational device is a patient-specific bone implant manufactured from titanium alloy Ti-6Al-4V using metal additive manufacturing technology. The implant is designed individually for each patient based on medical imaging data (CT or MRI), which are converted from DICOM format into three-dimensional digital models for anatomical reconstruction and implant design. The device is fabricated using selective laser melting (SLM) technology, in which high-power laser beams selectively fuse layers of Ti-6Al-4V powder to produce the final implant geometry. The manufacturing process is performed on a metal additive manufacturing system under an inert gas environment to prevent oxidation and ensure material integrity. Titanium powder feedstock complies with ASTM F2924 specifications for medical-grade Ti-6Al-4V used in powder bed fusion processes. Following printing, implants undergo standardized post-processing procedures including support removal, surface cleaning and finishing, stress-

06

What researchers measure

Primary outcomes

  1. Number of Participants with Major Postoperative Complications

    Assessment of major postoperative complications related to the implant or surgical procedure (Yes/No), based on clinical examination and medical record review.

    Time frame: 1-4 weeks postoperatively and from 6 weeks up to 12 months postoperatively

  2. Number of Participants with Early Local Complications

    Assessment of early local complications including wound discharge, bleeding, swelling, pain, and sensory disturbance, evaluated using standardized clinical examination.

    Time frame: Within 4 weeks postoperatively

  3. Number of Participants with Early Systemic Complications

    Assessment of early systemic complications including sepsis, hemodynamic instability, and respiratory failure, based on clinical evaluation and inpatient medical records.

    Time frame: Within 4 weeks postoperatively

  4. Number of Participants with Late Implant-Related Complications

    Assessment of late implant-related complications including implant loosening, sinus tract formation, and persistent pain, evaluated through clinical examination.

    Time frame: From 6 weeks up to 12 months postoperatively

  5. Change in C-reactive Protein (CRP) Level

    CRP levels (mg/L) will be measured using standard laboratory blood tests as an indicator of systemic inflammatory response following implantation.

    Time frame: Within 4 weeks postoperatively and from 6 weeks up to 12 months postoperatively

  6. Change in White Blood Cell (WBC) Count

    WBC count (×10⁹/L) will be measured using standard hematology tests as an indicator of infection or systemic inflammatory response.

    Time frame: Within 4 weeks postoperatively and from 6 weeks up to 12 months postoperatively

  7. Operative Time

    Duration of the surgical procedure measured in minutes, recorded from surgical records.

    Time frame: Intraoperative period

  8. Estimated Blood Loss

    Estimated intraoperative blood loss measured in milliliters (mL), recorded from surgical records.

    Time frame: Intraoperative period

Secondary outcomes

  1. Number of Participants with Implant Stability (No Implant Loosening)

    Assessment of implant stability defined as absence of implant loosening (Yes/No), evaluated by clinical examination and imaging (X-ray or CT).

    Time frame: At 3, 6, and 12 months postoperatively

  2. Rate of Successful Bone-Implant Integration on Imaging

    Assessment of osseointegration based on imaging findings (X-ray or CT), defined as absence of radiolucent lines and presence of a stable bone-implant interface.

    Time frame: At 3, 6, and 12 months postoperatively

  3. Number of Participants with restoration of Anatomical Structure

    Assessment of postoperative anatomical reconstruction (e.g., limb morphology) using clinical evaluation and imaging documentation.

    Time frame: Postoperative period and at 12 months postoperatively

  4. Change in Pain Score Measured by Visual Analog Scale (VAS)

    Pain intensity will be assessed using the Visual Analog Scale (VAS), a standardized 0-10 scale, with higher scores indicating greater pain.

    Time frame: Baseline and at 1, 3, 6, and 12 months postoperatively

  5. Change in Functional Outcome Score

    Functional outcomes will be assessed using validated patient-reported outcome measures, depending on the anatomical site of implantation: * Upper extremity: Disabilities of the Arm, Shoulder and Hand (DASH) score (range: 0-100; higher scores indicate greater disability and worse function) * Lower extremity: Lower Extremity Functional Scale (LEFS) (range: 0-80; higher scores indicate better functional status)

    Time frame: Baseline and at 3, 6, and 12 months postoperatively

  6. Change in Health-Related Quality of Life (SF-36 Score)

    Health-related quality of life will be assessed using the Short Form-36 Health Survey (SF-36), a validated patient-reported outcome measure. The SF-36 includes eight domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health), which are summarized into Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. Scores range from 0 to 100, with higher scores indicating better health-related quality of life.

    Time frame: Baseline and at 12 months postoperatively

  7. Number of Participants with Limb Length Discrepancy

    Assessment of limb length discrepancy (Yes/No), evaluated using clinical examination and imaging.

    Time frame: From 6 weeks up to 12 months postoperatively

07

Study locations

1 site
  • 3D Technology in Medicine Center (3D Lab, VinUni)
    Hanoi, 100000, Vietnam
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07540156
Lead sponsor
VinUniversity
Collaborators
Vinmec Healthcare System
Responsible party
Sponsor
First posted
Apr 20, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 20, 2026

Study contacts

Trung Dzung Tran, Professor, PhD, MD
Contact
dung.tt@vinuni.edu.vn
+84983762005

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion